| Project/Area Number |
26870877
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
Biological pharmacy
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
Ryou-u Takahashi 国立研究開発法人国立がん研究センター, その他部局等, 研究員 (10625510)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん治療 / 乳がん / microRNA / がん幹細胞 |
|---|
| Outline of Final Research Achievements |
In the present study, we identified microRNA-27b (miR-27b) as a key regulator for the generation of cancer stem cells (CSCs). In breast caner, down-regulation of miR-27b induced the generation of side-population that shows CSC properties such as drug resistance and high tumorigenicity. MiR-27b reduced the side-population via direct repression of ectonucleotide pyrophosphatase 1 (ENPP1), which is involved in type II diabetes (T2D) development. ENPP1 induced the generation of the side-population by promoting the expression and cell surface localization of ABCG2. More importantly, a significant correlation between ENPP1 expression and breast tumor malignancy in clinical samples was observed. Overall, our study demonstrates that a T2D-associated gene plays an important role in the regulation of CSC properties and suggests that conventional chemotherapy with modulating miR-27b expression by RNA-based treatments may improve the therapeutic outcomes of breast cancer patients.
|
